ClinicalTrials.gg
CompletedNCT00388960Updated Nov 19, 2019

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

A Phase 2 interventional study of Amrubicin and Cisplatin in Small Cell Lung Cancer, sponsored by Celgene. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing cisplatin in Small Cell Lung Carcinoma — 2 open to participants now, 2 under way, none of them phase 3. Cisplatin · Small Cell Lung Carcinoma.

Enrollment
11th of 32
99 · median 62
Started
2006
with 5 others
Phase 2
15 of 33
2 open now
Registered
16th of 33
by date
Lead sponsor
1 of 33
Celgene

Among the 33 studies testing cisplatin in Small Cell Lung Carcinoma, this one is the 11th largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2006, is one of 15 in phase 2, and was the 16th registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 33 studies testing cisplatin in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing cisplatin in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The purpose of the study is to document the activity and safety of single agent amrubicin, amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line treatment in extensive disease small cell lung cancer.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • small cell lung cancer
  • amrubicin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ proven small cell lung cancer
  • Extensive disease
  • World Health Organization (WHO) performance status 0-2
  • Age 18 years or older
  • Normal baseline cardiac function
  • No prior systemic chemotherapy for small cell lung cancer
  • Adequate organ function including bone marrow, kidney, and liver
  • No history of interstitial lung disease or pulmonary fibrosis
  • No history of prior unless patient has been disease free for greater than 5 years, or the tumour was a non-melanoma skin cancer or in-situ carcinoma of the cervix
  • No pregnancy or breast feeding; patients of must agree to use an appropriate method of
  • Written before randomization

Exclusion criteria

Exclusion criteria:

  • Pre-existing peripheral neuropathy (greater than Grade 1, version 3.0)
  • Uncontrolled or severe cardiovascular disease
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Amrubicin

    Amrubicin 45mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.

    Drug: Amrubicin

  • Experimental
    Amrubicin plus Cisplatin

    Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> IV day 1 of each 21-day cycle until disease progression.

    Drug: Amrubicin · Drug: Cisplatin

  • Active comparator
    Cisplatin plus etoposide

    Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 each 21-day cycle until disease progression.

    Drug: Cisplatin · Drug: Etoposide

Interventions

  • Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression. Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.

  • Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression. Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.

  • Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.

06

What researchers measure

Primary outcomes

  1. Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)

    Time frame: Until Disease Progression

Secondary outcomes

  1. Toxicity

    Time frame: Until 30 days after last protocol treatment

  2. Progression-free survival

    Time frame: Until disease progression or death

  3. Overall survival

    Time frame: Until death

07

Study locations

25 sites
  • Algemeen Ziekenhuis Middelheim
    Antwerpen, 2020, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Universiteit Gent
    Gent, 9000, Belgium
  • U.Z. Gasthuisberg
    Leuven, 3000, Belgium
  • Domaine Universitaire du Sart-Tilman
    Liege, 1BE, Belgium
  • Centre Hospitalier Regional de la Citadelle
    Liege, 4000, Belgium
  • Clinique Sainte Elisabeth
    Namur, 5000, Belgium
  • Instituto Nazionale per la Ricerca sul Cancro
    Genova, 16132, Italy
  • Universita Degli Studi Di Udine
    Udine, 33100, Italy
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • The Netherlands Cancer Institute Antoni Van Leeuwenhoekziekenhuis
    Amsterdam, Netherlands
  • Medisch Spectrum Twente - Dept of Pulmonary Diseases
    Enschede, 7500 KA, Netherlands
  • Leiden University Medical Centre
    Leiden, 2300RC, Netherlands
  • Academisch Ziekenhuis Maastricht
    Maastricht, 6202, Netherlands
  • Isala Kliniek
    Zwolle, 8001, Netherlands
  • Medical University of Gdansk - Dept Radiotherapy
    Gdansk, 80211, Poland
  • Clatterbridge Centre for Oncology NHS Trust
    Bebington, Merseyside CH684JY, United Kingdom
  • University of Dundee - Ninewells Hospital
    Dundee, Scotland D01 9SY, United Kingdom
  • Belfast City Hospital
    Belfast, BT9 7AB, United Kingdom
  • Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
  • Princess Royal Hospital
    Hull, HU8 9HE, United Kingdom
  • Royal Marsden Hospital, London
    London, SM2 5PT, United Kingdom
  • Christie Hospital
    Manchester, M20 4BX, United Kingdom
  • Sir Bobby Robson Cancer Trials Research Centre
    Newcastle-Upon-Tyne, NE4 6BE, United Kingdom
  • Royal Marsden Hospital Lung Unit
    Sutton, (Surrey) SM2 5PT, United Kingdom
08

References and documents

Publications

  • O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16. PubMed 21684151 ↗
  • Liddell RP, Evans NS. May-Thurner syndrome. Vasc Med. 2018 Oct;23(5):493-496. doi: 10.1177/1358863X18794276. No abstract available. PubMed 30187833 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2006 to primary completion in Apr 2010, 41 months.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 41 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2006
First posted
Oct 17, 2006
StartActual
Nov 1, 2006
Primary completionActual
Apr 1, 2010
CompletionActual
Dec 1, 2010
Results delay requested
May 31, 2012
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00388960
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 17, 2006
Start date
Nov 1, 2006
Primary completion
Apr 1, 2010
Completion
Dec 1, 2010
Last update
Nov 19, 2019

Study contacts

Mary O'Brien, MD
principal investigator · Royal Marsden Hospital, London, UK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amrubicin · Cisplatin

Start the discussion